ATS 2022 Highlights Podcast

In this episode (23:06 min), Medicom’s correspondent covers 6 presentations from the American Thoracic Society, which I attended in person in San Francisco, CA, USA from 13-18 May 2022.

1. Novel PDE4B inhibitor offers breakthrough for IPF
   Findings from a phase 2, randomised, placebo-controlled trial in patients with idiopathic pulmonary fibrosis (IPF) showed that the investigational drug BI 1015550, either alone or with background use of an anti-fibrotic agent, significantly prevented a decrease in lung function.
2. MANDALA and DENALI pattern success for albuterol-budesonide in asthma
   In patients with uncontrolled moderate-to-severe asthma, the risk of asthmatic exacerbation was significantly reduced when patients used a fixed-dose inhaler with a combination of albuterol and budesonide as-needed compared with the use of an inhaler with albuterol alone as-needed, in a dose-dependent manner. A second clinical trial confirmed that both components contributed to albuterol/budesonide efficacy, with the combinations demonstrating superior effects on lung function
3. Is avacopan better than prednisone for respiratory ANCA-associated vasculitis outcomes?
   An exploratory subgroup analysis of the phase 3 ADVOCATE trial showed that avacopan was only somewhat better than prednisone at reducing respiratory, as well as ear, nose, and throat (ENT), involvement in patients with ANCA-associated vasculitis. However, reduced glucocorticoid use in the avacopan group was a clear clinical benefit.
4. Colistimethate sodium PROMISing for non-cystic fibrosis bronchiectasis
   In the phase 3 PROMIS clinical program, the use of colistimethate sodium powder for nebulisation solution reduced pulmonary exacerbations in adults with non-cystic fibrosis bronchiectasis (NCFB) and Pseudomonas aeruginosa.
5. PAGANINI phase 2b data promising for eliapixant
   Presented 12-week dose-ranging results in patients with refractory chronic cough indicate efficacy for selective P2X3 antagonist eliapixant, although a single liver safety signal warrants intensified monitoring going forward.
6. NAVIGATOR steers asthma patients to tezepelumab
   Patients with severe, uncontrolled asthma demonstrated overall 2.8-fold higher odds of improved clinical responses to tezepelumab than placebo, including exacerbation reduction, better asthma control, improved lung function, and clinician assessment.

Enjoy listening!

Copyright ©2022 Medicom Medical Publishers

 



Posted on 9 June 202226 July 2024